KR101876177B1 - Transdermal botulinum toxin patch - Google Patents

Transdermal botulinum toxin patch Download PDF

Info

Publication number
KR101876177B1
KR101876177B1 KR1020160018213A KR20160018213A KR101876177B1 KR 101876177 B1 KR101876177 B1 KR 101876177B1 KR 1020160018213 A KR1020160018213 A KR 1020160018213A KR 20160018213 A KR20160018213 A KR 20160018213A KR 101876177 B1 KR101876177 B1 KR 101876177B1
Authority
KR
South Korea
Prior art keywords
botulinum toxin
patch
enhancer
layer
delete delete
Prior art date
Application number
KR1020160018213A
Other languages
Korean (ko)
Other versions
KR20170096689A (en
Inventor
이훈범
박문서
Original Assignee
가톨릭관동대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가톨릭관동대학교산학협력단 filed Critical 가톨릭관동대학교산학협력단
Priority to KR1020160018213A priority Critical patent/KR101876177B1/en
Publication of KR20170096689A publication Critical patent/KR20170096689A/en
Application granted granted Critical
Publication of KR101876177B1 publication Critical patent/KR101876177B1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

A transdermally permeable botulinum toxin patch is disclosed. The botulinum patch applied with the composition containing the botulinum toxin and the enhancer substance for promoting the percutaneous permeation of the substance can be easily transplanted with botulinum and can be continuously injected while applying the patch. Do.

Description

Transcutaneous botulinum toxin patch {TRANSDERMAL BOTULINUM TOXIN PATCH}

The present invention relates to a transcutaneous permeable botulinum toxin patch, particularly to a botulinum toxin patch for applying a botulinum toxin to a patch formulation for use in skin treatment.

Skin wrinkles are caused by stress, hormones, family history, and aging. The wrinkles caused by muscle contraction occur vertically in the direction of muscle contraction. The wrinkles due to aging are caused by endogenous aging which causes fine lines, skin sagging due to reduction of skin elasticity, and photoaging by ultraviolet rays which breaks elastic fibers of the dermal layer and causes rough and deep wrinkles.

Because skin wrinkles caused by various causes are not good for cosmetics, we try to improve wrinkles regardless of age and sex. In recent years, cosmetic surgery and cosmetic medicine have been widely used as a method of improving wrinkles. Botulinum toxins, which have been used for 10 years and have been proved to be safe, are widely used.

Botulinum toxin is widely used as a cosmetic for medical treatments or botulinum toxins as a filler to improve wrinkles. However, when the injectable botulinum toxin filler is used as a medical treatment, the effect is certain, but it is recognized that people are treated as medical treatment for molding, and there is a feeling of discomfort and pain due to injection. In addition, when the botulinum toxin is used as a patch or a product in the form of a cosmetic product, there is a problem that it is difficult to obtain a wrinkle-reducing effect because the transcutaneous permeability of the botulinum toxin, which is a high molecular substance of 150 kDa, is low.

Therefore, there is a demand for development of formulations having a wrinkle-improving effect, which can be easily used without displeasure by people.

Korean Patent Laid-Open Publication No. 10-2013-0122016 (2013.11.06) U.S. Patent No. 8404249 (Mar. 23, 2013)

SUMMARY OF THE INVENTION The present invention has been made to solve the above-mentioned problems, and it is an object of the present invention to provide a patch to which a composition containing a botulinum toxin and an enhancer promoting transdermal permeation is applied.

As a technical means to achieve the above-mentioned technical object, the percutaneous transmission patch according to one aspect of the present invention contains botulinum toxin and an enhancer substance which promotes transdermal permeation.

The botulinum toxin may be one or more selected from the group consisting of types A, B, C, D, E, F and G.

The botulinum toxin may be administered in an amount of 0.01 unit to 300 units.

The enhancer may be an enhancer that makes the botulinum toxin endoplasmic reticulum and / or an enhancer that dilates the blood vessel.

The enhancer may be at least one selected from the group consisting of pyrrolidone derivatives, fatty acid derivatives having a carbon chain of C 8-18 , or triacetin.

The enhancer may be nitroglycerin.

The botulinum toxin patch may be composed of a composition containing layer containing the composition and a substrate layer supporting the composition containing layer.

The substrate layer may be a substrate layer having a magnet embedded in a hole formed in the substrate or a substrate layer having a separate magnet layer attached thereto.

The botulinum toxin patch may be one in which at least one layer constituting the botulinum toxin patch is made of a breathable material.

The transdermal permeable botulinum toxin patch may be a micro needle patch.

The microneedle patch may further comprise a local anesthetic.

The local anesthetic may be one or more selected from the group consisting of dibucaine, lidocaine, mefibacaine, and ethidocaine

The microneedle patch may be coated with a composition containing the dermatitis treating material, an enhancer for promoting transdermal permeation of the dermatitis treating material, and a local anesthetic agent.

Since the botulinum toxin patch of the present invention can be transcutaneously penetrated, it can be easily injected through the skin, and the botulinum toxin can be injected continuously while the patch is attached, thereby exhibiting excellent skin permeability and wrinkle reduction effect compared to simple application .

FIG. 1 shows a result of measurement of percutaneous permeability of a patch manufactured according to an embodiment of the present invention.
FIG. 2 shows a result of measuring blood flow increase due to vasodilation in a patch manufactured according to an embodiment of the present invention.
3 is a conceptual diagram of a cross section of a botulinum toxin patch according to an embodiment of the present invention.
4 is a conceptual diagram of a cross section of a botulinum toxin patch including a magnet according to an embodiment of the present invention.
5 is a conceptual diagram of a cross section of a botulinum toxin patch in which a magnet layer according to an embodiment of the present invention is attached to a substrate layer.
6 is a conceptual diagram of a cross section of a micro needle botulinum toxin patch according to an embodiment of the present invention.

Hereinafter, the present invention will be described in more detail. However, it should be understood that the present invention is not limited thereto, and the present invention is only defined by the scope of the following claims.

The present invention provides an percutaneous permeation patch capable of injecting botulinum toxin through the transdermal skin of human skin by increasing transdermal permeability.

The percutaneous transmission patch 100 according to one aspect of the present invention contains botulinum toxin and an enhancer material that promotes transdermal permeation of the botulinum toxin.

The botulinum toxin may preferably be at least one selected from the group consisting of types A, B, C, D, E, F and G, more preferably type A or B. A to G refer to a botulinum serotype classified through an immunological discrimination method of a botulinum toxin.

The botulinum toxin improves the wrinkles of the skin by using a pharmacological mechanism in which the toxin acts on the neuromuscular junction to inhibit acetylcholine release and blocks nerve conduction, thereby suppressing muscle contraction at the site and causing muscle palsy.

The botulinum toxin is preferably administered in an amount of 0.01 unit to 300 units, more preferably 0.1 unit to 200 units, in one administration. A unit means the ratio of the toxin showing half the mortality rate when injecting botulinum toxin into the abdominal cavity of a mouse (1 mouse IP LD50 = 1 Unit). If the dose of botulinum toxin is less than 0.1 unit, there may be no effect of improving wrinkles caused by botulinum toxin. If it exceeds 300 units, general feeling of weakness may occur. The unit may be included in the composition by dilution depending on where the patch is applied.

The enhancer may be an enhancer that makes the botulinum toxin endoplasmic reticulum and / or an enhancer that dilates the blood vessel.

The enhancer substance which makes the botulinum toxin into an endoplasmic reticulum may preferably be one or more selected from the group consisting of alcohol, pyrrolidone derivative, fatty acid derivative having a carbon chain of C 8-18 and triacetin.

Examples of pyrrolidone derivatives include N-cyclohexyl-2-pyrrolidone, 1-butyl-3-dodecyl-2 pyrrolidone, 1,5-dimethyl-2-pyrrolidone, 1-ethyl-2-pyrrolidone, Methyloxycarbonyl-2-pyrrolidone, 1-hexyl-2-pyrrolidone, 1- (2-hydroxy- Pyrrolidone, 3-hydroxy-N-methyl-2-pyrrolidone, 1-lauryl- 1-lauryl-4-methyloxycarbonyl-2-pyrrolidone, N-methyl-2-pyrrolidone, N-caprylyl- 2-pyrrolidone, N-dodecyl-2-pyrrolidone, and the C 8-18 aliphatic derivatives are preferably glycerol lauryl alcohol glycerol lauryl alcohol, oleyl alcohol, propylene glycol monooleate, isopropyl myristate, sorbitan mono-oleate, propylene monolaurate, propylene mono-oleate, oleyl macrogolglyceride, oleic acid oleic acid, lauroyl macrogoglyceride, linoleoyl macrogoglyceride, propylene glycol caprylate / caprate, sorbitan monostearate monoacetate, But are not limited to, sorbitan monostearate mono-oleate, glycerol monolaurate, propylene glycol monolaurate, propylene glycol monocaprylate, sorbitan monolaurate, sorbitan monolaurate, monolaurate, lauryl lactate, caprylic / capri < RTI ID = 0.0 > c triglyceride, corn oil PEG-8 ester, and corn oil PEG-6 ester. More preferred are N-dodecyl-2-pyrrolidone, Lauryl pyrrolidone, glycerol monooleate, glycerol monolaurate, propylene glycol monolaurate, propylene glycol monocaprylate, Sorbitan monolaurate, and sorbitan monolaurate.

For the transdermal permeation of botulinum toxin, the incensors create an endoplasmic reticulum containing a dermatitis treatment material, which allows intercellular pathways between the keratinocytes of the skin.

The enhancer material that extends the blood vessel may preferably be nitroglycerin. These materials can temporarily increase blood flow to the patched site as a vasodilator to increase transdermal absorption of the drug.

The above-mentioned alcohol, pyrrolidone derivative, a fatty acid derivative having a carbon chain of C 8-18 and an enhancer for forming an endoplasmic reticulum such as triacetin and an enhancer for expanding blood vessels such as nitroglycerin may be used at the same time, have.

The botulinum toxin patch 100 may be composed of a composition containing layer 120 containing the composition and a substrate 110 supporting the composition containing layer. The composition-containing layer 120 may be prepared by stacking a plurality of layers such as a storage layer, a release rate-controlling layer, and a pressure-sensitive adhesive layer of a composition according to the purpose, method, and site of use of the botulinum toxin patch 100, May be produced in the form of a checkerboard having an independent region between the composition and the phosphor.

The substrate 110 may be a substrate having a magnet 140 embedded in a hole formed in the substrate 110 or a substrate having a separate magnet layer 130 attached thereto. The magnetic field generated by the N and S poles of the magnet 140 penetrates the skin into the skin, thereby expanding the blood vessels at the patch attachment site. The expansion of blood vessels can improve blood circulation and thus increase the transdermal permeability of botulinum toxin. In addition, the magnet 140 promotes the secretion of cytokines and can simultaneously induce analgesic and anti-inflammatory effects.

The substrate 110 may be a substrate in which at least one hole is present and the magnet 140 is embedded in the hole. Or a magnet layer 130 comprised of one or more magnets 140 is attached to the substrate layer 110. The botulinum toxin patch in which the magnet layer 130 is attached to the substrate layer 110 may be in the form that the composition-containing layer 120, the substrate 110, the magnet layer 130, etc. are piled up, The order of stacking the composition-containing layer 120, the substrate 110, and the magnet layer 130 can be arbitrarily set.

The magnet 140 may be used regardless of the shape of a circle, a rod, etc., and may include one or more magnets 140. In addition, the magnets 140 may be located at arbitrary intervals throughout the patch, and may be located at arbitrary intervals only in necessary portions.

In the botulinum toxin patch 100, at least one layer constituting the botulinum toxin patch 100 may be made of a breathable material. The toxicity of botulinum toxin causes serious side effects such as hypersensitivity reactions such as allergies or shocks to humans. The breathable material can provide fresh air to the patched skin. When air inside and outside of the patch made of breathable material is circulated, the toxicity of the botulinum toxin contained in the patch can be discharged to the outside together with the circulated air. When the toxin of the botulinum toxin is released, side effects such as allergies, shock waves, rashes and itching can be minimized. The breathable material may be a single layer or a multilayer, and may be made of various materials depending on the purpose, method, and site of use, such as natural fibers, synthetic fibers, ceramics, and films.

The breathable material may have a structure in which pores penetrate from the innermost face, which is the skin adhesion face, to the outermost face, which is the air contact face. When pores penetrate, external air comes into contact with the skin, and it is easy to control the temperature and humidity of the skin. The pores can control the degree of penetration of pores and the size of pores according to the method of use, purpose and site of the botulinum toxin patch 100.

The botulinum toxin patch may be a micro needle patch 102. The Mylar needle 150 may have a conical shape or a pyramid shape, and the needle may be formed to a length of 20 mu m to 1000 mu m. The microneedles 150 are preferably selected from solid microneedles, formulated microneedles, coated microneedles, hollow microneedles, and the like. And more preferably, coated microneedles with a drug.

The micro needle patches 102 may further include a local anesthetic. The topical anesthetic is preferably an ester type such as ***e, procaine chloroprocaine, tetracaine, dibucaine, lidocaine, And an amide type such as mepivacaine, etidocaine, and the like. More preferably an amide type topical anesthetic, and even more preferably lidocaine.

The local anesthetic agent may be coated on the outer surface of the microneedle 150 or contained in the microneedle 140 and used to reduce the pain felt by the user when the microneedle 140 touches the skin.

The botulinum toxin patch may be a botulinum toxin patch coated on a micro needle 140 with a composition containing a botulinum toxin, an enhancer that promotes transdermal permeation of the botulinum toxin, and a local anesthetic agent.

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily carry out the present invention. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.

Comparative Example  : Preparation of Patches Applied with Botulinum Toxin

The botulinum toxin (MEDITOXIN, manufactured by Meditox) was evenly mixed with the adhesive solution and applied on the silicone-treated release paper at a width of 9 cm 2 using a laboratory-coating unit. The coating material was dried and then adhered to the substrate.

Example  1: botulinum toxin and N- Dodecyl -2- Pyrrolidone  ≪ / RTI >

The solution mixed with botulinum toxin (MEDITOXIN, Meditox) and N-dodecyl-2-pyrrolidone (Lauryl pyrrolidone) was evenly mixed with the adhesive solution, The coating was applied in a 9 cm 2 area using a coating unit. The coating material was dried and then adhered to the substrate.

Example  2: Manufacture of magnetic patch

The solution mixed with botulinum toxin (MEDITOXIN, Meditox) and N-dodecyl-2-pyrrolidone (Lauryl pyrrolidone) was evenly mixed with the adhesive solution, The coating was applied in a 9 cm 2 area using a coating unit. Ferrite magnets were attached to the substrate at regular intervals, and then the dried coatings were attached.

Example  3: Micro needle  Manufacture of patches

Poly lactic acid was placed in a microneedle mold prepared from a microneedle master structure using polydimethylsiloxane, and the polymer was melted in a vacuum oven at 70 ° C and filled with a polymer in a mold cavity under a reduced pressure of 70 kPa. Polymer was removed from the stomach with hardened polymer at room temperature to prepare poly lactic acid micro needle. The fabricated needle has a bottom width of 250 μm, a height of 600 μm, a pyramid shape in the form of a three-dimensional shape, and 400 microneedles per 100 mm 2 area.

The coating solution prepared by mixing the botulinum toxin and N-dodecyl-2-pyrrolidone (Lauryl pyrrolidone) on the micro needles was dropped by 30 μm with a micropipette, And then adhered to the substrate with an adhesive.

Example 4: Preparation of a patch coated with botulinum toxin and nitroglycerin

A solution of botulinum toxin (MEDITOXIN, manufactured by Meditox) and nitroglycerine was mixed with the adhesive solution and applied on the silicon-treated release paper at a width of 9 cm 2 using a laboratory-coating unit. The coating material was dried and then adhered to the substrate.

Example  5: Manufacture of magnetic patch

A solution of botulinum toxin (MEDITOXIN, manufactured by Meditox) and nitroglycerine was mixed with the adhesive solution and applied on the silicon-treated release paper at a width of 9 cm 2 using a laboratory-coating unit. Ferrite magnets were attached to the substrate at regular intervals, and then the dried coatings were attached.

Experimental Example  : Transdermal administration  exam

SD rats weighing 250-300 g were used for 7 days. The experimental model was sacrificed by cervical dislocation method and the skin was cut and removed. The extracted skin was directly transferred to the cell culture medium and experiments were carried out within 24 hours so that the metabolism activity could be maintained as much as possible. The prepared patch was attached to the skin, filled with 12.5 ml of buffer solution, and placed in an incubator at 37 ° C. At 6, 24, 48 and 72 hours, sampling was taken with a syringe and filled with buffer solution. A phosphate buffered sine (pH 7.4) was added to a Franz-type diffusion cell having a diffusion area of 1.77 cm 2 , and the mixture was stirred at 600 rpm while maintaining the temperature at 37 ° C. The area of the skin contacting the receptor compartment was 7.7 cm 2 and the volume was 12.5 mL. The analytical samples were collected and refrigerated for 12 hours, and analyzed by HPLC within 12 hours. The results are shown in Table 1 below.

Accumulative amount permeated, ug / cm 2 Time (h) Comparative Example Example 1 Example 2 Example 3 0 0 0 0 0 6 13 32 34 53 24 52 93 100 123 48 98 197 186 254 72 124 286 292 395

As shown in Table 1, it was found that the patches of Examples 1 to 3 had a larger amount of the transcutaneous botulinum toxin than the patches of the comparative example, and that the patch of Example 3 was more percutaneous than the patches of Examples 1 and 2 It was found that the amount of botulinum toxin permeated was large.

Experimental Example  : Vasodilation test

30 adult men aged 35 to 40 years, weighing 75 kg to 85 kg, were classified into experimental groups by 10 persons, and the patches of Comparative Examples, Examples 4 and 5 were attached to their calves. The external temperature was set at 25 ° C and the external humidity was set at 60%. We restricted the intake of all food, including water, 1 hour before the experiment. A laser Doppler blood perfusion imager was used and the calf was patched and irradiated with a low power laser beam with a wavelength of 670 nm. The blood perfusion was measured indirectly by frequency change measurement and converted to perfusion units (PU). Each measurement is expressed as a mean value.

Mean PU Time (h) Comparative Example Example 4 Example 5 0 134.72 132.63 133.15 6 139.32 153.78 167.32 Growth rate 3.5% 16% 26%

As shown in Table 2 above, the patches of Examples 4 and 5 showed an increase in the average blood flow at the patch-attached portions as compared with the patches of the comparative example. From the above results, it was confirmed that the patches of Examples 4 and 5 expanded blood vessels and increased blood flow.

According to the above experimental examples, it was confirmed that the enzyme was a substance to help transcutaneous permeation of botulinum toxin, and when the micro needle patch was produced, the transcutaneous permeation of botulinum toxin was more actively generated than the general patch. In addition, in the case of the magnet patch, although the percutaneous permeation effect of the botulinum toxin of the magnet patch itself was also effected, the transcutaneous permeation effect of the botulinum toxin was further increased when it was used as an enhancer for expanding the blood vessel.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments. It will be possible. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive. For example, each component described as a single entity may be distributed and implemented, and components described as being distributed may also be implemented in a combined form.

As the base of the patch in the present invention, various excipients that help percutaneous permeation, which are commonly known in the field to which the present invention belongs, and pressure-sensitive adhesives that help skin sticking can be used, and within the scope of not hindering the object of the present invention, Skin irritation relief can be added.

The scope of the present invention is defined by the appended claims rather than the detailed description and all changes or modifications derived from the meaning and scope of the claims and their equivalents are to be construed as being included within the scope of the present invention do.

100: botulinum toxin patch 101: magnetic botulinum toxin patch
102: Micro needle patch 110: substrate layer
120: composition-containing layer 130: magnet layer
140: Magnet 150: Micro needle
160: composition coating layer

Claims (13)

Botulinum toxin; And
An enhancer substance which promotes transdermal permeation of the botulinum toxin
≪ / RTI > is applied,
Wherein the botulinum toxin is at least one selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G,
The botulinum toxin is administered in an amount of 0.01 to 300 units,
Wherein the enhancer is at least one selected from the group consisting of an enhancer for making the botulinum toxin an endoplasmic reticulum and an expander for expanding a blood vessel, and the enhancer for making the botulinum toxin into an endoplasmic reticulum is a pyrrolidone derivative, As a botulinum toxin patch, which is a nitroglycerin,
Wherein the botulinum toxin patch comprises a composition containing layer containing the composition; And
And a substrate layer for supporting the composition containing layer,
Wherein the substrate layer is a substrate layer having a magnet embedded in a hole formed in the substrate or a substrate layer having a separate magnet layer attached thereto. delete delete delete delete delete delete delete The method according to claim 1,
The botulinum toxin patch comprises
Wherein at least one of the layers constituting the botulinum toxin patch is made of a breathable material. The method according to claim 1,
The botulinum toxin patch comprises
A botulinum toxin patch that is a micro needle patch. delete delete 11. The method of claim 10,
The micro needle patch comprises:
A botulinum toxin patch comprising a botulinum toxin and a composition comprising an enhancer material that promotes transdermal permeation of the botulinum toxin.
KR1020160018213A 2016-02-17 2016-02-17 Transdermal botulinum toxin patch KR101876177B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020160018213A KR101876177B1 (en) 2016-02-17 2016-02-17 Transdermal botulinum toxin patch

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160018213A KR101876177B1 (en) 2016-02-17 2016-02-17 Transdermal botulinum toxin patch

Publications (2)

Publication Number Publication Date
KR20170096689A KR20170096689A (en) 2017-08-25
KR101876177B1 true KR101876177B1 (en) 2018-07-09

Family

ID=59761712

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160018213A KR101876177B1 (en) 2016-02-17 2016-02-17 Transdermal botulinum toxin patch

Country Status (1)

Country Link
KR (1) KR101876177B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116764088A (en) * 2018-08-15 2023-09-19 阿勒根公司 Microneedle array with active ingredient
KR20200090500A (en) * 2019-01-21 2020-07-29 가천대학교 산학협력단 Micro-needle patch and method of mamufacture for palmar hyperhidrosis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050025320A (en) * 2002-07-11 2005-03-14 알러간, 인코포레이티드 Transdermal botulinum toxin compositions
JP2005306746A (en) * 2004-04-19 2005-11-04 Jiyugaoka Clinic Wrinkle therapeutic agent for face
KR20070018047A (en) * 2004-03-03 2007-02-13 레반스 테라퓨틱스 Compositions and methods for topical application and transdermal delivery of botulinum toxins
KR20080072717A (en) * 2005-11-17 2008-08-06 레반스 테라퓨틱스, 아이엔씨. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
KR20140010425A (en) * 2011-03-07 2014-01-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Microneedle devices and methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050025320A (en) * 2002-07-11 2005-03-14 알러간, 인코포레이티드 Transdermal botulinum toxin compositions
KR20070018047A (en) * 2004-03-03 2007-02-13 레반스 테라퓨틱스 Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2005306746A (en) * 2004-04-19 2005-11-04 Jiyugaoka Clinic Wrinkle therapeutic agent for face
KR20080072717A (en) * 2005-11-17 2008-08-06 레반스 테라퓨틱스, 아이엔씨. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
KR20140010425A (en) * 2011-03-07 2014-01-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Microneedle devices and methods

Also Published As

Publication number Publication date
KR20170096689A (en) 2017-08-25

Similar Documents

Publication Publication Date Title
KR100764156B1 (en) Intradermal-penetration agents for topical local anesthetic administration
RU2428179C2 (en) Preparative forms of medications against dementia for transcutaneous introduction
JPH02115131A (en) Method for lowering skin stimulation relating to drug/penetration accelerating composition
KR20130000370A (en) Transdermally absorbed preparation of anti-dementia drug
KR101876177B1 (en) Transdermal botulinum toxin patch
Memariani et al. Emerging and novel therapies for keloids: a compendious review
US11273114B2 (en) Compound additive having biological activation function, preparation method therefor and use thereof
KR20160128888A (en) Soluble microneedle patch for tranexamic acid delivery
KR102560152B1 (en) Microneedle for accelerating percutaneous absorption
KR101876176B1 (en) Transdermal patch containg bee venom extracts
EP1214944A1 (en) Percutaneous absorption agents
KR102509435B1 (en) Soluble microneedle patch for delivery of atopic dermatitis drug
CN108354922B (en) Medicinal preparation for treating diabetic chronic ulcer and preparation method thereof
KR102631435B1 (en) Soluble microneedle patch for delivery of drug for contusion
JP2005306746A (en) Wrinkle therapeutic agent for face
KR101605711B1 (en) Microneedle coated by oriental medicine compositions and method for manufacturing thereof
KR20130022602A (en) Transdermal drug delivery system and preparation method thereof
KR102399484B1 (en) Soluble microneedle patch for delivery of antipsoriatic drug
KR20170132570A (en) Soluble microneedle patch for delivery of alopecia drug
CN111544593A (en) Microneedle patch carrying anti-psoriasis systemic drug and preparation method thereof
CN108514569A (en) Oblique application of the leaf Lignum Santali Albi extract in preparing skin wound healing drug
KR20120102747A (en) Transdermally absorbed preparation of anti-dementia drug
RU2804809C1 (en) Method for manufacturing biodegradable microneedle skin patch for delayed hemostimulation of cancer patients
CN103040795B (en) Rotundine transdermal patch and preparation method thereof
Cheng et al. A biomimetic micropillar wound dressing with flavone and polyphenol control release in vitro and in vivo

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant